Appropriate use of muscle relaxants in anaesthesia, intensive and emergency care

Leo H.D.J. Booij

Abstract

In this short review are the physiological processes involved in neuromuscular transmission described. Muscle relaxants are used in clinical anaesthesia to block this transmission and the requirements for an ideal drug are defined. The disadvantages of the currently available drugs are summarized including those for succinylcholine. Some focus is placed on rocuronium. The main disadvantage, i.e. residual paralysis, can be treated and/or prevented by reversal of such a block. However, currently used compounds have serious adverse effects and are not always efficacious. Therefore also the requirements for an ideal reversal agent are defined. Against this profile is sugammadex discussed. The possibility to replace succinylcholine with a combination of succinylcholine and sugammadex is discussed.

Keywords: neuromuscular transmission, neuromuscular block, succinylcholine, rocuronium, residual block, sugammadex

The introduction of muscle relaxants into routine clinical anaesthesia in 1942 by Griffith and Johnson has tremendously changed the practice of anaesthesia and increased the surgical possibilities to the benefit of mankind. Nowadays muscle relaxation is an irreplaceable part of anaesthesia, intensive and emergency care. Its use is indicated for endotracheal intubation, facilitation of surgery, and immobilisation of patients. When administered appropriately it contributes to the safety of the patient, but when used inappropriately it leads to increased morbidity and mortality. Knowledge of the pharmacology of the muscle relaxants therefore is very important for the clinician administering this type of drugs to their patients.

Neuromuscular transmission

The motor endplate is the place where the stimulus is transferred from the nerve to the skeletal muscle [1]. The transfer of the stimulus is chemically mediated by acetylcholine, which is produced in the mitochondria of the nerve cell, and is stored in presynaptic vesicles. Upon stimulation of the nerve a fast sodium channel opens, starting depolarization of the nerve membrane. Upon such depolarization is an acetylcholine vesicle mobilized and moves from the acetylcholine stored toward the presynaptic membrane, where it approaches the active zone. The number of vesicles and thus the amount of acetylcholine mobilized depends on the rate of nerve stimulation. The vesicles bind via an avalanche of peptide interactions (v-snares and t-snares) to the cell wall, and the vesicle membrane fuses with the cell membrane. This process of mobilization, binding and fusion of vesicles is called vesicle trafficking or exocytosis. Thus acetylcholine is released by fusion of the membranes into the synaptic cleft and it then diffuses across this cleft to reach the postsynaptic membrane where it binds to the acetylcholine receptors. This binding activates the receptor where upon its ion channel opens, causing a depolarization of the muscle cell membrane. The depolarization opens L-type voltage-gated calcium channels (dihydropyridine receptors) in the t-tubule membrane. Conformational changes in L-type calcium channels following depolarization allow calcium to enter the skeletal muscle sarcoplasm. The conformational change in L-type calcium channels induces a conformational change in...
an adjacent calcium release channel (Ryanodine receptor) located in the membrane of the sarcoplasmic reticulum (SR) of the muscle cell. This results in a rapid calcium influx, which calcium binds to troponin C on the actin myofilament, and leads to the initiation of cross-bridge cycling of the muscle in the process known as excitation-contraction coupling [2]. This causes the muscle to contract. Then acetylcholine dissociates from the receptor and repolarization of the membrane can occur, allowing the next depolarization. Acetylcholine is partly metabolized by acetylcholinesterase in the synaptic cleft, and partly it is taken up again in the presynaptic terminal (recycling). Also the vesicle membrane is recycled and used again for the production of new vesicles. This process of recycling is called endocytosis [3]. Many drugs and toxins (snake bites etc.) do interfere with the vesicle trafficking process and result in paralysis or muscle weakness.

Recycled and newly synthesized acetylcholine is collected in vesicles. The process of the mobilization of acetylcholine vesicles is influenced by presynaptic acetylcholine receptors. When increase in muscle activity occurs, then there is decrease in the amount of acetylcholine released, when there is decrease in activity there is increase in acetylcholine release and also receptor production stimulation. Occupation of these receptors by non-depolarizing relaxants result in fading in the response to train of four or tetanic stimulation. The constituents of the postsynaptic acetylcholine receptors are produced in the muscle cells and assembled into receptors under the influence of peptides released from the nerve terminal together with acetylcholine. When there is no release of acetylcholine in the neuromuscular junction (immobilization or denervation) the production of receptor elements increases (up regulation) and the receptors spread along the muscle membrane. When there is acetylcholine release the receptors concentrate and are fixed at the motor endplate. A number of peptides is involved in the process of assembly and fixation of the receptors. If the release of acetylcholine increases the number of receptors decreases (down regulation). This up and down regulation results clinically in respectively tachyphylaxis and sensitization for muscle relaxants [4].

The ideal neuromuscular blocking agent

None of the presently available muscle relaxants meets the criteria for the ideal neuromuscular blocking agent as described by Savarese and Kitz. They defined 3 types of relaxants: fast onset and short duration, intermediate duration, or long duration, all without side effects and with a non-depolarizing mechanism of action [5]. It has been recognised that the onset of action of the relaxants is depending on the potency of the compounds; i.e. the less potent the faster the onset [6]. Also other requirements for an ideal relaxant have been defined: i.e. non-depolarising mechanism of action, fast onset, non-cumulative, without cardiovascular side-effects or histamine release, prompt and complete reversal with anticholinesterases, rapid elimination from the body independent from renal and/or liver function or transformation into inactive metabolites [7]. Muscle relaxants seem to be responsible for 50% of the adverse reactions during anaesthesia. The most frequent reactions are tachycardia, cardiovascular collapse, urticaria, and bronchospasm. Such reactions most frequently occur after succinylcholine, followed by the benzylisoquinoline relaxants, whereas they are rarely noticed after steroidal relaxants. Skin tests demonstrated the relative freedom of histamine release with the steroidal relaxants [8]. Especially pipercuronium, vecuronium are free from adverse effects. With rocuronium pain on injection and a slight increase in blood pressure and heart rate may occur. With rocuronium a higher incidence of anaphylactoid reactions than with other relaxants has been reported from France, Norway and New Zealand, but not from other countries. It is the substituted ammonium groups in the relaxants which evoke the allergic reactions. It has been proven that such an effect coincides with the use of pholcodine containing drugs [9, 10]. Studies revealed that pholcodine sensitizes the immune system, leading to increased IgE release. This drug is in the mentioned countries free available and can explain the higher incidence of anaphylactoid reactions to muscle relaxants and especially rocuronium in those countries.

Neuromuscular blocking agents

The currently used neuromuscular blocking agents affect the nicotinic acetylcholine receptor at the postjunctional membrane in the neuromuscular junction. Some of the compounds, mainly older, also have an inhibiting effect on other acetylcholine receptors, which results in side effects. The clinically used relaxants can be divided in depolarizing and non-depolarizing relaxants with respectively an agonistic and antagonistic effect on the receptor. The only clinically used depolarizing relaxant is succinylcholine. The non-depolarizing relaxants can be roughly divided in compounds with a benzylisoquinoline structure (d-tubocurarine, atracurium, cisatracurium, mivacurium, doxacurium) and steroidal relaxants (pancuronium, pipercuronium, vecuronium, rocuronium). Besides some non-depolarizing relaxants with other structures are available (gallamine, alloferine), but their clinical use has largely diminished. A depolarizing neuromuscular blockade is characterized by a fast onset of action, the occurrence
of muscle fasciculations (because of its agonistic effect) and the lack of fading in the response to train of four or tetanic stimulation. A non-depolarizing neuromuscular blockade does not have fasciculations, and shows fade in the response to train of four or tetanic stimulation. Succinylcholine has to occupy about 25% of the receptors before its effect is shown in decreased muscle contractility, whereas the non-depolarizing relaxants have to occupy 70-75% of the receptors to show such an effect [11]. The effect of succinylcholine cannot be reversed whereas acetylcholinesterase inhibitors (neostigmine, pyridostigmine, edrophonium) can reverse a non-depolarizing neuromuscular blockade. The benzylisoquinoline relaxants are known to be able to cause histamine release with bronchoconstriction, hypotension, and tachycardia. In some cases anaphylactoid reactions occur with all muscle relaxants. The newer benzylisoquinolines are metabolized in the plasma by Hoffman degradation and ester hydrolysis, they are largely independent from organ function. Most steroidal relaxants are metabolized in the liver and excreted via urine, they thus depend for their pharmacodynamic profile on organ function.

**Succinylcholine**

Succinylcholine was introduced in the clinic in 1951. Fast metabolism by plasma (pseudo)-cholinesterase causes a quick recovery of the resulting blockade. Plasma cholinesterase is produced in the liver and is available in an abundant amount in the plasma. This indicates that the duration of action of succinylcholine is prolonged in severe liver disease. Succinylcholine is, because of its usually short duration of action, mainly used for endotracheal intubation of the patients. For longer lasting effects it can be administered by continuous infusion, but than a so called phase II block can occur. Such phase II block has the characteristics of a non-depolarizing neuromuscular blockade, can be reversed by neostigmine and is most likely caused by desensitization of the acetylcholine receptor. Succinylcholine provides excellent intubation conditions in most cases. Most anaesthetists believe the duration of action to be 5 minutes. However, it is well known that the duration of action of succinylcholine in the usual intubating dose of 1 mg/kg is having a duration of action between 10 and 15 minutes with a large variability. Such variability depends on the plasma cholinesterase activity in the individual patient [12]. Many factors cause variability in plasma cholinesterase activity:

a. genetic disorders causing either low concentration or presence of atypical cholinesterase

b. inhibition of plasma cholinesterase by drugs like metoclopramide, ubretid, esmolol, echotiophate, donepezil, terbutaline, and cyclophosphamide
c. malnutrition or presence of solenoids from potatoes
d. plasmapheresis, cardiopulmonary bypass and hemodialysis
e. organophosphate intoxication
f. chronic administration of neostigmine or pyridostigmine
g. massive blood transfusion or blood exchange
h. burn trauma

Succinylcholine has many side effects such as bradycardia, especially on repeated administrations, muscle fasciculations, myalgia, increase in intraocular, intracranial, and intragastric pressure, and potassium release resulting in hyperkalaemia. Such potassium release occurs when there is up-regulation of acetylcholine receptors, which leads to extra-junctional fetal receptor types [13].

**What are the main clinical problems with the non-depolarizing muscle relaxants?**

Non-depolarizing neuromuscular blocking agents can have adverse effects [14]. The benzylisoquinoline relaxants are known to be able to cause histamine release with bronchoconstriction, hypotension, and tachycardia. In some cases anaphylactoid reactions occur. A common problem with all relaxants is the wide variability in the pharmacodynamic behaviour. The pharmacodynamic effect of non-depolarizing muscle relaxants is depending on numerous factors:

a. pharmacological profile of the relaxant (long, intermediate, short)
b. concurrent diseases (liver, kidney, inflammation, neuromuscular)
c. concurrent medication (antibiotics, anti-epileptics, etc.)
d. body temperature
e. acid-base balance (acidosis, alkalosis)
f. type and depth of anaesthesia (inhalational, MAC)
g. gender of the patient
h. age
i. body weight / composition of the patient (volume of distribution)

j. haemodynamics in the patient (slow, fast circulation)

Because all these factors can differ from patient to patient, the variability in effect of muscle relaxants is not surprising. Variability in effect may result in residual paralysis which in turn may cause postoperative pulmonary complications [15-17]. The incidence of postoperative residual paralysis is at average 40-50%, frequently despite routine administration of neostigmine [18-20]. Full recovery only exists when the train of four ratio is above 0.9, because below this value disturbances in hypoxic drive, insufficient airway patency maintenance, and swallowing disorders do occur. From the many studies can it be concluded that there are
three important factors in preventing residual paralysis: 1. only using the available shortest acting muscle relaxants, 2. routinely objective monitoring of neuromuscular transmission, and 3. routinely reverse neuromuscular block. For this reason most anaesthetists currently only use intermediate long acting muscle relaxants (rocuronium, vecuronium, atracurium, cis-atracurium). However, routine monitoring is globally rarely practised, whereas routine reversal is practised only in a few countries.

Rocuronium bromide

Rocuronium is an amino-steroidal relaxants with a fast onset and an intermediate duration of action [21]. The ED90-95 is 0.3-0.4 mg/kg. After a dose equal to two times the ED90-95 dose, i.e. 0.9-1.0 mg/kg, the intubation under good to excellent conditions is possible in 60-90 seconds [22]. Rocuronium can cause a slight increase in heart rate and a small rise in blood pressure, presumably due to the pain on injection. Pain on injection occurs more frequently in female than in male [23]. It has been demonstrated that this pain can be prevented by previous administration of ketamine, dexmedetomidine, lidocaine, and by diluting the solution with saline. However also magnesium, sodium carbonate, fentanyl, and alfentanil seem to be effective. This indicates that the pain originates from an unspecified mechanism of action. From my own and others experiences must it be concluded that this pain is only observed during light planes of anaesthesia. The pain is without further sequels like thrombo-phlebitis. There is some fear that rocuronium causes a higher incidence of anaphylactoid reactions than other non-depolarizers. However, allergy and anaphylactoid reactions after its administration has been mainly reported from France, Norway, and Australia, but not in other countries [24-26]. This is possibly related to the free use of pholcodine, which sensitizes the immune system, in those countries. Since this was noticed is pholcodine taken of the market in Norway and has the reporting of anaphylactoid reactions with rocuronium there decreased.

Reversal of neuromuscular blockade

The ability to reverse the effect of the muscle relaxants is one of basic requirements for muscle relaxation. Until recently only the anti-cholinesterases neostigmine, pyridostigmine and edrophonium were clinically used for this purpose. Acetylcholinesterase plays an important role in neuromuscular transmission by eliminating the acetylcholine molecules from the cleft through hydrolytic transformation. Only 50% of the acetylcholine molecules liberated from the nerve terminal actually reach the postsynaptic receptors, the rest is hydrolysed before that. Although anticholinesterases do also have a direct presynaptic effect, it is believed that their main reversing mechanism is through inhibition of acetylcholinesterase. The presynaptic effects lead to repetitive firing and increased acetylcholine release. These effects also contribute to the reversing activity. For the reversal of neuromuscular blockade neostigmine is considered the standard compound. The onset of action of neostigmine is slow, for complete reversal 10 minutes or more are needed depending on at what degree of blockade the agent was administered. A problem with the cholinesterase inhibitors is that their effect depends on the type and depth of anaesthesia. Furthermore can deep blockades not be reversed by neostigmine, because of a ceiling effect indicating that if all cholinesterase is blocked no further blockade of the enzyme can take place [27]. Besides, anticholinesterases cause an increase of acetylcholine at all receptor places (nicotinic and muscarinic), resulting in side effects like bradycardia, arrhythmia, excessive secretions from salivary and bronchial glands, and increased bronchial and intestinal smooth muscle tone. The adverse effects are dose dependent, and are most pronounced with neostigmine and least pronounced with edrophonium [28]. The drugs, except edrophonium, also inhibit plasma cholinesterase activity, thus they prolong the effect of succinylcholine and mivacurium. The decrease in plasma cholinesterase activity lasts for 30-60 minutes. At repeated dosages of anti-cholinesterases neuromuscular block may occur from transient depolarisation of the receptors, and blockade of open confirmation channels [29, 30].

Atropine, but especially glycopyrrolate prevents many of the cardiovascular effects of the anticholinesterases, but, it is not able to prevent the intestinal effects. At least for neostigmine in one study it has been demonstrated that it increases the incidence of nausea and vomiting in the immediate postoperative period [31, 32]. For a long time, because of all these side-effects, an ideal reversal agent has been searched. At first new cleaner compounds with an anticholinesterase effect were studied, but proved to have similar side-effects as neostigmine [33]. Then a completely new method of reversal was developed, using molecular encapsulation [34]. Finally sugammadex (org 25969), a modified γ-cyclodextrine that encapsulates vecuronium and rocuronium and thereby inactivates these molecules, was selected as a potential ideal reversing agent [35].

What is an ideal reversal agent?

In the process of developing new drugs the requirements for such a drug have to be defined. This is also
applied to the development of drugs reversing the effect of neuromuscular blocking agents. Especially the many side effects of the anticholinesterases had to be absent in such a drug. Therefore in my opinion the requirements for an ideal neuromuscular block reversing agent should be that the drug must:

a. provide full reversal within 1-3 minutes
b. reverse each depth of neuromuscular block
c. be independent from type and level of anaesthesia
d. be independent from acid-base balance
e. reverse relaxant-drug combination block (antibiotics, magnesium, etc.)
f. be free from adverse-effects
g. reverse in patients with organ disease (liver, kidney)
h. not leave the possibility of recurarization
i. be rapidly excreted from the body, or be readily metabolised
j. be free from allergic reactions
k. be effective in patients with neuromuscular disease
l. be applicable in all age groups
m. be effective against all relaxants
n. be not affected by hypothermia

Sugammadex

Sugammadex is a specific binding agent (encapsulation) for steroidal muscle relaxants [36, 37]. The compound is not metabolised, but both sugammadex and the sugammadex-rocuronium complex are rapidly excreted in the urine. It has a dose depending fast onset of action, which allows complete recovery of a neuromuscular block of any degree within 2-4 minutes [38, 39]. It, however, is only effective with steroidal, but not with benzylisoquinoline muscle relaxants [40]. It reverses successfully superficial, deep and profound neuromuscular blockades induced by rocuronium or vecuronium [41-43]. It is also effective after repeated doses or continuous infusion of rocuronium or vecuronium [44, 45]. Contrary to neostigmine the effect is independent from the type and depth of anaesthesia [46], from temperature, and from acid-base balance. Because of its mechanism of action (encapsulation of the rocuronium-vecuronium molecule) does it not interfere with acetylcholine, its receptor, or any other receptor, therefore is it unlikely that relevant adverse effects on the cardiovascular system or respiratory tract will occur. Sugammadex has been successfully administered in elderly and children [47], in patients with pulmonary disease, and in patients with cardiovascular disturbances [48]. Also in patients with renal dysfunction it was effective and the recurarization did not occur [49]. If after administration of sugammadex a new neuromuscular blockade is requested, either a non-steroidal relaxant or a higher dose of rocuronium can be used [50]. The recovery of a combination of rocuronium and sugammadex is faster than the recovery of succinylcholine, and provides identical intubation conditions [51]. Sugammadex does not encapsulate endogenous substances or other drugs.

Can rocuronium replace succinylcholine?

There is a number of disadvantages to the use of succinylcholine. As explained above succinylcholine is a drug with many side-effects, but with an excellent pharmacodynamic profile (fast onset, short duration, fast recovery). In my opinion, because of its side effects and especially the possibility of hyperkalaemia, it is obsolete in Intensive Care patients and should be replaced in anaesthesia whenever this is possible.

It is impossible to reach acceptable intubation conditions in all patients with succinylcholine in the usually administered doses (0.5-1.0 mg/kg) [52]. Therefore nowadays doses of 1.0-1.5 mg/kg are advised. The duration of action of succinylcholine is widely variable because of the large variability in plasma cholinesterase activity. Although many anaesthesists believe the duration of action of an intubating dose (1-1.5 mg/kg) to be only 5 minutes it is in many cases longer than 10 minutes. This can easily lead to unacceptable hypoxia. Benumoff et al. modelled oxygen saturation during succinylcholine-induced apnoea, and found remarkable result [53]. They stated that “...in the large majority of patients with 1 mg/kg of succinylcholine induced apnea, significant life threatening haemoglobin desaturation will occur before functional recovery”. In a study by Heier et al. these results were verified in patients [54]. Significant haemoglobin desaturation occurred in one third of the subjects during the period of apnoea from a dose of 1 mg/kg succinylcholine, despite only young healthy subjects were included in the study. The degree of desaturation correlated with the duration of apnoea. Especially children are prone to early hypoxia because they have a smaller functional residual capacity. Patients with pre-existing disease processes that compromise lung function have a higher risk to develop desaturation because their functional residual capacity is markedly lower than in young healthy subjects. Patients in labour and those with obesity or sepsis have considerably accelerated arterial desaturation, while the oxygen consumption is also higher [55]. It is known that during apnoea the rate of desaturation is rapidly increasing because the volume in the alveoli is decreasing, leading to alveolar collapse and increasing ventilation/perfusions disturbances, leading to shunting [56]. In obese patients and pregnant patients can pre-oxygenation in the sitting position delay the desaturation with about 1 minute [57]. This, however, may be insufficient to prevent hypoxia,
due to the variability of succinylcholine’s effect. Furthermore, at values of saturation below 80%, the saturation curve enters the steep part and the saturation than changes more rapidly with small changes in arterial oxygen partial pressure. Some authors have suggested that lower dosages of succinylcholine increase the margin of safety for hypoxia because of a shorter duration of the apnea, while providing acceptable intubation conditions [58, 59]. However, in such cases the intubation conditions were poor, resulting in delayed intubation and increased risk on hypoxia. It has recently been shown that patients who received succinylcholine as the neuromuscular blocking agent for intubation developed significantly faster oxygen desaturation than those who received rocuronium [60]. There was a relation with the severity of the fascinations after succinylcholine, also an increase in CO₂ excretion was observed.

All these facts indicate that succinylcholine is far from an ideal relaxant agent and that is not as safe as most anaesthetists believe.

For this reason has it long been looked for a steroidal non-depolarising replacement drug. However, none of the potential drugs were free from severe side-effects and therefore were not further developed [61, 62]. In order to replace succinylcholine must the compound have a fast onset and short duration of action with rapid recovery and must it provide excellent to good intubating conditions. Rocuronium approved to be a candidate for the replacement of succinylcholine because of its short onset of action, which in high dosages is similar as that of succinylcholine, and because of its rather clean safety profile. However, in the doses required rocuronium has a markedly longer duration of action than succinylcholine. From all the currently available non-depolarising relaxants rocuronium has the fastest onset of action that provide the possibility to have excellent to good intubating conditions within 1-1.5 minutes, similar to succinylcholine [63-65]. This also is true in paediatric cases [66-68]. An advantage of rocuronium over succinylcholine is that it does not cause bradycardia and does not increase intraocular and intracranial pressure [69]. In many institutions throughout the world, because of its better safety profile, rocuronium replaced succinylcholine for rapid sequence intubation. The only disadvantage that rocuronium is having compared to succinylcholine, is a longer duration of action. But the specific steroidal relaxant binding compound sugammadex has been proven to be able to reverse a rocuronium blockade of any degree within 2-3 minutes when administered in adequate doses [70-73]. It reverses contrary to neostigmine, independent from the type and depth of anaesthesia [74, 75]. Sugammadex reverses much faster than neostigmine to full recovery within a few minutes [76, 77]. This may be an opportunity to customize the duration of action of rocuronium for intubating situations. While a large dose of rocuronium approaches succinylcholine in onset, the rapid reversal of rocuronium with sugammadex exceed the speed of spontaneous recovery from succinylcholine. This indeed has been proven in patients and we are awaiting the results of further studies in this direction [78, 79]. Together, the rocuronium-sugammadex sequence promises to achieve what other novel neuromuscular blocking and reversing drugs have not provided: to retire succinylcholine. The combination indeed has clinical value [80]. Not only the old slogan “So Long, Six!” but also “So Long, Neostigmine!” may come true if sugammadex proves itself in clinical practice [81]. It now appears that suxamethonium can be replaced even for its final remaining indications.

**Conclusion**

Residual paralysis is a real problem in the post-operative period and contributes to the morbidity and mortality of anaesthesia. Administration of neostigmine, besides the possibility of many adverse effects, is no guarantee to prevent such residual paralysis. Sugammadex is currently the most ideal reversing agent and can prevent residual blockade in all situations. It furthermore provides in combination with rocuronium a possibility to exclude succinylcholine from further use.

**References**

36. Booij LHDJ, van Egmond J, Driessen JJ, de Boer HD. In vivo animal studies with sugammadex. Anaesthesia 2009; 64 (suppl 1): 38-44
42. de Boer HD, Driessen JJ, Marcus MA, Kerkkamp H, Heerling M, Klimek M. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study. Anesthesiology 2007; 107: 239-244
44. Shields M, Giovannelli M, Mirakhor RK, Moppett I, Adams J, Hermens Y. Org 25969 (sugammadex), a selective relaxant binding agent for antagonism of prolonged rocuronium-induced
neuromuscular block. Br J Anaesth 2006; 96: 36-43


52. Donati F. The right dose of succinylcholine. Anesthesiology 2003; 99: 1037-1038

53. Benumof JL, Dagg R, Benumof R. Critical hemoglobin desaturation will occur before return to an unparalyzed state following 1 mg/kg intravenous succinylcholine. Anesthesiology 1997; 87: 979-982


68. Fuchs-Bader T, Tassonyi E. Intubating conditions and time course of rocuronium-induced neuromuscular block in children. Br J Anaesth 1996; 77: 335-338


71. Booij LHDJ. Cycloedextrins and the emergence of sugammadex. Anaesthesia 2009; 64 (suppl 1): 31-37

72. Booij LHDJ, van Egmond J, Driessen JJ, de Boer HD. In vivo animal studies with sugammadex. Anaesthesia 2009; 64 (suppl 1): 38-44

73. Mirakhur RK. Sugammadex in clinical practice. Anaesthesia 2009; 64 (suppl 1): 45-54


78. Lee C, Jahr JS, Candiotti KA, Warriner B, Zornow MH, Naguib M. Reversal of profound neuromuscular block by sugammadex

**Cuvinte cheie:** transmisie neuromusculară, bloc neuromuscular, succinilcolină, rocuronium, bloc rezidual, sugammadex